Contributors |
|
ix | |
The Concept of Iatrogenicity |
|
1 | (4) |
|
|
|
|
|
|
|
Chapter 1 Iatrogenicity: Definition, History, and Modern Context |
|
|
5 | (11) |
|
|
|
|
Chapter 2 Epidemiology and Public Health Aspects and Implications of Iatrogenicity: Regulatory, Legal and Ethical Dimensions |
|
|
16 | (6) |
|
Miriam A. Gonzalez-Siegel |
|
|
|
Chapter 3 Risk Management: The Medical Center Administration Perspective |
|
|
22 | (6) |
|
|
Miriam A. Gonzalez-Siegel |
|
|
Chapter 4 Iatrogenicity from the Patient's Perspective |
|
|
28 | (6) |
|
|
Chapter 5 A Naturopathic Perspective on Iatrogenesis |
|
|
34 | (13) |
|
|
PART II Iatrogenicity of Cardiovascular Drugs and Cardiovascular Toxicity of Noncardiac Drugs |
|
|
|
|
|
Chapter 6 Clinical Manifestations of Acute and Chronic Drug-Induced Iatrogenic Cardiovascular Diseases and Syndromes |
|
|
47 | (15) |
|
|
|
|
|
|
Chapter 7 Drug-Induced Cardiac Arrhythmias and Sudden Cardiac Death |
|
|
62 | (15) |
|
|
|
|
Chapter 8 Chemotherapy-Induced Cardiomyopathy |
|
|
77 | (11) |
|
|
|
Chapter 9 Iatrogenicity of Blood Pressure Measurement in the Diagnosis of Hypertension |
|
|
88 | (13) |
|
|
|
|
Chapter 10 Antihypertensive Drug-Induced Iatrogenic Cardiovascular Syndromes |
|
|
101 | (15) |
|
|
|
Chapter 11 Iatrogenicity of Cardiovascular Drugs Associated With Cardiac and Noncardiac Toxicities: Antihypertensive Agents and Biologics |
|
|
116 | (27) |
|
Evelyn R. Hermes-DeSantis |
|
|
|
Chapter 12 Iatrogenic Aspects of Hypertension in Pregnancy: Focus on Preeclampsia |
|
|
143 | (13) |
|
|
|
Chapter 13 Women and Iatrogenic Cardiovascular Disease: Menopausal Estrogen as the Prime Suspect |
|
|
156 | (7) |
|
|
|
|
Chapter 14 Iatrogenic Aspects of Lipid-Lowering, Antiplatelet, and Anticoagulant Agents |
|
|
163 | (12) |
|
|
|
|
|
|
Chapter 15 Iatrogenic Effects of Urologic Drugs on the Cardiovascular System |
|
|
175 | (13) |
|
Konstantinos Stavropoulos |
|
|
|
|
|
|
Chapter 16 Iatrogenicity and Antianginal Drugs |
|
|
188 | (6) |
|
|
|
Chapter 17 Antidiabetic Drugs and Cardiovascular Risk: Where Do We Stand? |
|
|
194 | (11) |
|
|
Chapter 18 Cardiovascular Iatrogenicity in Older Adults |
|
|
205 | (16) |
|
|
|
|
|
|
|
|
PART III Iatrogenicity of Diagnostic and Therapeutic, Invasive and Noninvasive Cardiovascular Interventions, Devices, and Surgeries |
|
|
|
|
|
|
Chapter 19 Iatrogenic Aspects of Noninvasive and Invasive Diagnostic Methods in Interventional Cardiology |
|
|
221 | (12) |
|
|
|
|
Chapter 20 Iatrogenicity Associated With Interventional Treatment Modalities in Cardiology |
|
|
233 | (10) |
|
|
|
|
|
Chapter 21 Iatrogenicity of Diagnostic and Therapeutic, Invasive and Noninvasive Cardiovascular Interventions, Devices, and Surgeries |
|
|
243 | (12) |
|
|
|
|
|
|
Chapter 22 Iatrogenic Aspects of Cardiac Electrophysiology |
|
|
255 | (16) |
|
|
|
|
|
Chapter 23 Iatrogenic Aspects in Cardiac Device Therapy |
|
|
271 | (16) |
|
|
|
Chapter 24 Cardiovascular Iatrogenicity of Respiratory Therapeutic Modalities |
|
|
287 | (22) |
|
|
|
|
PART IV Iatrogenic Aspects of Sport Cardiology and Lifestyle Modifications |
|
|
|
|
|
|
Chapter 25 Trained Athletes |
|
|
309 | (9) |
|
|
|
|
Chapter 26 Sports Cardiology |
|
|
318 | (9) |
|
|
Chapter 27 Dangers of Lifestyle Modification Advice |
|
|
327 | (10) |
|
|
PART V Iatrogenicity of Dietary Supplements, Herbal Products, and Other Nontraditional Therapies in Cardiovascular Medicine |
|
|
|
|
|
|
Chapter 28 Safety of Dietary and Herbal Supplements: Side Effects and Contraindications |
|
|
337 | (33) |
|
|
|
|
|
|
Chapter 29 Interactions Between Supplements and Medications |
|
|
370 | (45) |
|
|
|
|
|
|
Index |
|
415 | |